Zydus Lifesciences reported Q4FY26 revenue growth of 16.2% YoY to ₹7,587 crore, while FY26 PAT increased 11.4% to ₹5,040 crore. The board approved a ₹1,100 crore share buyback at ₹1,150 per share and recommended a final dividend of Re 1 per share. EBITDA margin expanded to 31.2% during FY26.